Nicolas Andre

Summary

Country: France

Publications

  1. ncbi request reprint Has the time come for metronomics in low-income and middle-income countries?
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, AP HM, Marseille, France
    Lancet Oncol 14:e239-48. 2013
  2. ncbi request reprint Can targeted therapy be successful without metronomic scheduling?
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, Hopital pour Enfants de La Timone, Boulevard Jean Moulin, 13005 Marseille, France
    Curr Top Med Chem 12:1639-42. 2012
  3. pmc Pilot study of a pediatric metronomic 4-drug regimen
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, Hopital pour Enfants de La Timone, Marseille, France
    Oncotarget 2:960-5. 2011
  4. doi request reprint [Specificity of paediatric oncology pharmacology]
    N Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, AP HM, 264, rue Saint Pierre, 13385 Marseille Cedex 05, France
    Bull Cancer 97:191-8. 2010
  5. ncbi request reprint Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Marseille, France
    Clin Ther 30:1336-40. 2008
  6. doi request reprint [Metronomic chemotherapy in pediatric oncology: hype or hope?]
    N Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Boulevard Jean Moulin, 13005 Marseille, France
    Arch Pediatr 16:1158-65. 2009
  7. ncbi request reprint Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy
    Nicolas Andre
    Department of Pediatric Oncology, Children Hospital of La Timone, Marseille, France
    Anticancer Drugs 18:277-81. 2007
  8. ncbi request reprint Metronomic chemotherapy: Back to the future!
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, AP HM, Marseille, France
    Drug News Perspect 23:143-51. 2010
  9. ncbi request reprint Anti-angiogenic therapies for children with cancer
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Marseille, France
    Curr Cancer Drug Targets 10:879-89. 2010
  10. doi request reprint Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
    Nicolas Andre
    INSERM UMR 911, Cytosquelette et Intégration des Signaux du Micro Environnement Tumoral, CRO2, Universite d Aix Marseille, Marseille, France
    Future Oncol 7:385-94. 2011

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Has the time come for metronomics in low-income and middle-income countries?
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, AP HM, Marseille, France
    Lancet Oncol 14:e239-48. 2013
    ..We also highlight the need for adapted clinical study endpoints and innovative models of collaboration between for-profit and non-profit organisations, to address the growing problem of cancer in resource-limited countries...
  2. ncbi request reprint Can targeted therapy be successful without metronomic scheduling?
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, Hopital pour Enfants de La Timone, Boulevard Jean Moulin, 13005 Marseille, France
    Curr Top Med Chem 12:1639-42. 2012
    ..Here, we discuss the nature of the specificity of targeted anti-cancer treatments and conclude that optimizing the schedule is an effective way to improve treatment selectivity...
  3. pmc Pilot study of a pediatric metronomic 4-drug regimen
    Nicolas Andre
    Service d hématologie et oncologie pédiatrique, Hopital pour Enfants de La Timone, Marseille, France
    Oncotarget 2:960-5. 2011
    ..MC is gaining interest as an alternative strategy to fight resistant cancer...
  4. doi request reprint [Specificity of paediatric oncology pharmacology]
    N Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, AP HM, 264, rue Saint Pierre, 13385 Marseille Cedex 05, France
    Bull Cancer 97:191-8. 2010
    ..Such a research is now encouraged and facilitated by a European regulation as well as by international consortia such as "Innovative Therapies for Children with Cancer" (ITCC)...
  5. ncbi request reprint Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Marseille, France
    Clin Ther 30:1336-40. 2008
    ..Metronomic chemotherapy (MC) is the administration of chemotherapy at doses below the maximal tolerated dose on a frequent schedule of administration, with no prolonged drug-free breaks...
  6. doi request reprint [Metronomic chemotherapy in pediatric oncology: hype or hope?]
    N Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Boulevard Jean Moulin, 13005 Marseille, France
    Arch Pediatr 16:1158-65. 2009
    ..We review the data regarding the use of metronomic chemotherapy in children with cancer and discuss its potential uses and limits...
  7. ncbi request reprint Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy
    Nicolas Andre
    Department of Pediatric Oncology, Children Hospital of La Timone, Marseille, France
    Anticancer Drugs 18:277-81. 2007
    ..Safety and efficacy of pegfilgrastim must be compared with filgrastim and evaluated in younger children with lower body weight...
  8. ncbi request reprint Metronomic chemotherapy: Back to the future!
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, AP HM, Marseille, France
    Drug News Perspect 23:143-51. 2010
    ..Based on recent insights in the various mechanisms of action, we will try to predict the potential new developments of metronomic chemotherapy in oncology...
  9. ncbi request reprint Anti-angiogenic therapies for children with cancer
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Marseille, France
    Curr Cancer Drug Targets 10:879-89. 2010
    ..This review will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer...
  10. doi request reprint Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
    Nicolas Andre
    INSERM UMR 911, Cytosquelette et Intégration des Signaux du Micro Environnement Tumoral, CRO2, Universite d Aix Marseille, Marseille, France
    Future Oncol 7:385-94. 2011
    ..In this article, we explain why MSAT represents a very attractive strategy for developing next-generation multitarget therapies...
  11. ncbi request reprint [How pediatric residents involve children during medical decision-making?]
    N Andre
    Département d oncologie pédiatrique, hôpital pour enfants de lt lt La Timone gt gt, Marseille, France
    Arch Pediatr 12:1068-74. 2005
    ..To describe how pediatric residents involve children during medical decision-making and evaluate the relationship between practice patterns and residents characteristics...
  12. ncbi request reprint Molecular effects of cyclosporine and oncogenesis: a new model
    N Andre
    Pediatric Oncology Department, Children Hospital of La Timone, Bd Jean Moulin, 13885 Marseille Cedex 5, France
    Med Hypotheses 63:647-52. 2004
    ..This new insights into the mechanisms of genesis of cyclosporine A-related cancers should be taken into account to develop preventive strategies or new immunosuppressive strategies...
  13. ncbi request reprint FDG PET and evaluation of posttherapeutic residual tumors in pediatric oncology: preliminary experience
    Nicolas Andre
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, Marseille, France
    J Pediatr Hematol Oncol 30:343-6. 2008
    ..The determination of their nature (fibrosis or active tumor) is crucial. The place of 18F-fluorodeoxyglucose -positron emitting tomography (PET) as a new imaging device remains to be determined in this context...
  14. doi request reprint Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF
    Emilie Milano-Bausset
    Département d oncologie pédiatrique, Hopital pour Enfants de La Timone, Assistance Publique des Hopitaux de Marseille, Marseille, France
    Clin Ther 31:2388-95. 2009
    ..Pegfilgrastim is a pegylated filgrastim with a longer plasma half-life that is administered once per cycle...
  15. ncbi request reprint Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis
    Manon Carre
    UMR CNRS 6032, Faculty of Pharmacy, University of La Méditerranée, 27 Boulevard Jean Moulin, 13005 Marseille, France
    Biochem Pharmacol 63:1831-42. 2002
    ..Our results show that As(2)O(3) and paclitaxel act antagonistically on mitochondria and microtubules and illustrate the need for careful evaluation of drug combinations...
  16. doi request reprint Novel mutations in TTC37 associated with tricho-hepato-enteric syndrome
    Alexandre Fabre
    Service de Pédiatrie Multidisciplinaire, Hopital d Enfants de la Timone, Marseille, France
    Hum Mutat 32:277-81. 2011
    ..In contrast, TTC37 is not expressed in the liver, an organ that is not consistently affected in THE syndrome. Last, we suggested a model for the putative structure of the unknown Thespin protein...
  17. doi request reprint Exclusion of EGFR, HRAS, DSP, JUP, CTNNB1, PLEC1, and EPPK1 as functional candidate genes in 7 families with syndromic diarrhoea
    Alexandre Fabre
    Service de Pédiatrie Multidisciplinaire, Hopital d Enfants de la Timone, Marseille, France
    J Pediatr Gastroenterol Nutr 48:501-3. 2009
    ..Using direct sequencing or linkage analysis, we excluded all of the candidate genes as the disease-causing gene in our group of patients; however, the hypothesis of intercellular junctions defect in SD remains seductive...
  18. ncbi request reprint Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma
    Emilie Milano
    Department of Pharmacy, Children Hospital of La Timone, Marseille, France
    Anticancer Drugs 17:1231-4. 2006
    ..So far, pemetrexed associated with cisplatin revealed a good tolerance and promising results regarding its antitumoral efficacy in a progressive metastatic abdominal mesothelioma in childhood...
  19. pmc SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome
    Alexandre Fabre
    UMR_S 910, INSERM Faculté de Médecine, Aix Marseille Universite, Marseille, France
    Am J Hum Genet 90:689-92. 2012
    ..Our results show that mutations in genes encoding cofactors of the human Ski complex cause syndromic diarrhea, establishing a link between defects of the human exosome complex and a Mendelian disease...
  20. ncbi request reprint Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells
    Nicolas Andre
    UMR 6032, University of La Méditerranée, UFR of Pharmacy, 27 Bd Jean Moulin, 13005 Marseille, France
    FEBS Lett 532:256-60. 2002
    ..Thus, paclitaxel targets mitochondria upstream of caspase activation, early during the apoptotic process in intact human neuroblastoma cells...
  21. ncbi request reprint Involving children in paediatric oncology decision-making
    Nicolas Andre
    Paediatric Oncology, La Timone Children s Hospital, Marseille, France
    Lancet Oncol 5:467. 2004
  22. doi request reprint Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
    Romain Guilhaumou
    Aix Marseille Univ, CRO2, INSERM, UMR 911, 13385 Marseille, France
    Cancer Chemother Pharmacol 68:1633-8. 2011
    ..We subsequently assessed the impact of ABCB1 polymorphisms on intracellular vincristine accumulation...
  23. ncbi request reprint Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment
    Eddy Pasquier
    FRE CNRS 2737, CISMET Cytosquelette et Integration des Signaux du Micro Environnement Tumoral, University of Aix Marseille, 27 Bd Jean Moulin, 13005 Marseille, France
    Curr Cancer Drug Targets 7:566-81. 2007
    ..We will also review and discuss the potential clinical development and the limitations of MTAs used as tumour-specific anti-vascular molecules...
  24. doi request reprint Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples
    Romain Guilhaumou
    Laboratoire de Pharmacocinétique et Toxicologie, Hopital de la Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France
    J Chromatogr B Analyt Technol Biomed Life Sci 878:423-7. 2010
    ..A rapid, specific and sensitive LC/MS/MS method for quantification of vincristine in human plasma was developed and is now successfully applied for pharmacokinetic studies in paediatric patients...
  25. ncbi request reprint Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I
    N Andre
    Multidisciplinary Pediatric Department, Children s Hospital of La Timone, Boulevard Jean Moulin, 13885, Marseille Cedex 5, France
    J Inherit Metab Dis 28:103-6. 2005
    ..We report the case of a child who developed severe obstructive hypertrophic cardiomyopathy revealing hereditary tyrosinaemia type I, who was successfully treated with NTBC. The mechanisms underlying the association are discussed...
  26. ncbi request reprint [Antimitochondrial agents: a new class of anticancer agents]
    N Andre
    Service d Oncologie Pediatrique, EA3286, Hopital pour Enfants de La Timone, 13005 Marseille, France
    Arch Pediatr 13:69-75. 2006
    ..The acknowledgement of mitochondria as a new target for anticancer agents provides a new way to bypass cancer cell chemoresistance...
  27. ncbi request reprint Metronomics: towards personalized chemotherapy?
    Nicolas Andre
    Service d Hématologie and Oncologie Pédiatrique, AP HM, 264 rue Saint Pierre, 13385 Marseille, France
    Nat Rev Clin Oncol 11:413-31. 2014
    ..In this Review, we foresee the future developments of metronomic chemotherapy and specifically its potential role in the era of personalized medicine. ..
  28. doi request reprint Neurocognitive function after radiotherapy for paediatric brain tumours
    Laetitia Padovani
    Department of Radiation Oncology and Paediatrics, CHU La Timone, Assistance Publique des Hopitaux de Marseille, 264 Boulevard Jean Moulin, 13005 Marseille, France
    Nat Rev Neurol 8:578-88. 2012
    ....
  29. ncbi request reprint Taxanes in paediatric oncology: and now?
    Nicolas Andre
    Department of Paediatric Oncology, EA3286, UFR of Medicine and La Timone Children Hospital, Bd Jean Moulin, 13885 Marseille, Cedex 5, France
    Cancer Treat Rev 32:65-73. 2006
    ..Thus, although the initial experience with taxanes in paediatric oncology has been disappointing, it may be too early to leave out taxanes and we should further investigate their use among children with cancer...
  30. doi request reprint [Gastrointestinal stromal tumours in pediatrics: a summary of the literature on this orphan disease]
    Arnauld Verschuur
    Hopital d Enfants de la Timone, Service d Oncologie Pediatrique, Marseille, France
    Bull Cancer 98:79-86. 2011
    ....
  31. doi request reprint Solitary, extracutaneous, skull-based juvenile xanthogranuloma
    Andre Maues de Paula
    Department of Anatomic Pathology and Neuropathology, 264 rue Saint Pierre, Centre Hospitalier Universitaire La Timone, 13005 Marseille, France
    Pediatr Blood Cancer 55:380-2. 2010
    ..Partial surgical resection, chemotherapy, and conformational radiotherapy were used. Exclusive extracutaneous JXG with an intracranial, vertebral, or skull-based localization is extremely rare...
  32. doi request reprint Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases
    Céline Chappe
    Department of Pediatric Oncology, Pontchaillou University Hospital, Rennes, France
    Childs Nerv Syst 29:565-71. 2013
    ..We focused on primary GC involving exclusively gray matter in a pediatric population in order better to define the presentation and outcome of this disease...
  33. doi request reprint Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends
    Marie Laure Couec
    Service d Oncologie Pediatrique, CHU Nantes, Nantes, France
    Pediatr Blood Cancer 59:34-8. 2012
    ....
  34. doi request reprint CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations
    Joseph Ciccolini
    Laboratoire de Pharmacocinetique, La Timone University Hospital of Marseille, UMR 911, Aix Marseille University, Marseille, France
    Pharmacogenomics 13:393-7. 2012
    ..This case demonstrates that besides affecting thiopurine methyltransferase, dysregulations with CDA should be screened to anticipate toxicities with the cytarabine plus mercaptopurine combination...
  35. pmc Hidden chromosomal abnormalities in pleuropulmonary blastomas identified by multiplex FISH
    Benoit Quilichini
    Departement de Genetique Medicale, CHU hôpital d enfants La Timone, Bd Jean Moulin, 13385 Marseille Cedex 5, France
    BMC Cancer 6:4. 2006
    ..Pleuropulmonary blastoma (PPB) is a rare childhood dysontogenetic intrathoracic neoplasm associated with an unfavourable clinical behaviour...
  36. ncbi request reprint Intractable diarrhea with "phenotypic anomalies" and tricho-hepato-enteric syndrome: two names for the same disorder
    Alexandre Fabre
    Multidisciplinary Paediatric Department, Children Hospital of La Timone, Boulevard Jean Moulin, Marseille Cedex, France
    Am J Med Genet A 143:584-8. 2007
    ..The acknowledgment that these two syndromes represent the same disease is a crucial step toward a better description of this syndrome and its outcome toward studies of the underlying genetic cause...
  37. doi request reprint [Evaluation of a screening strategy after occurrence of two simultaneous contaminating tuberculosis cases in a pediatric oncology department]
    A Gauchon
    Service d Oncologie Pediatrique, Hopital pour Enfants de La Timone, 13385 Marseille Cedex 05, France
    Arch Pediatr 15:236-44. 2008
    ..Nevertheless, antituberculosis agent expose to increased toxic effects and immunocompromised patients have an increased risk of experiencing progression of latent mycobacterium tuberculosis infection to active tuberculosis disease...